

PRODUCT INFORMATION

Uniprot ID P15692

 $\label{eq:apx003;APX-003;BD0801;BD-0801;TK001;TK-001;Sevacizumab (not WHO assigned INN)} APX003;APX-003;BD0801;BD-0801;TK001;TK-001;Sevacizumab (not WHO assigned INN) APX003;APX-003;BD0801;BD-0801;TK001;TK-001;Sevacizumab (not WHO assigned INN) APX003;APX-003;BD0801;BD-0801;TK-001;TK-001;Sevacizumab (not WHO assigned INN) APX003;APX-003;A$ **Common Name**

Synonyms VPF:VEGF:MVCD1:L-VEGF

N/A **Applications** Recommended N/A Dilutions

Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please

Formulation & Reconstitution see Certificate of Analysis for specific instructions of

reconstitution.

Host Species Whole mAb

lgG1 IgG type Reactivity Human **VEGFA Target**

Description Anti-VEGFA(suvemcitug biosimilar∏lgG1) mAb

Delivery

Store at -20°C to -80°C for 12 months in lyophilized form. After Storage & Shipping

reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.

> Email: info@dimabio.com Website: www.dimabio.com

Background

Usage Research use only Conjugate Unconjugated

Address: Wuhan institute of Biotechnology B7, Biolake No.666 Gaoxin Road, Wuhan, Hubei, China Telephone: +1 2409940618(USA) /+86-18062749453(China)

/+86-400-006-0995(China)

